目的 探討羧甲司坦聯(lián)合丙卡特羅治療小兒支氣管哮喘的臨床療效。方法 選取2021年6月-2023年7月天津市人民醫(yī)院兒科收治的80例支氣管哮喘患兒,按照治療方式的不同分對(duì)照組和治療組,每組各40例。對(duì)照組患兒口服鹽酸丙卡特羅口服溶液,3 mL/次,1次/d。治療組在對(duì)照組的治療基礎(chǔ)上口服羧甲司坦片,0.5片/次,3次/d。兩組均連續(xù)治療7 d。觀察兩組的臨床療效和癥狀消失時(shí)間,比較治療前后兒童哮喘控制測(cè)試(C-ACT)評(píng)分、血清炎性因子水平。結(jié)果 治療后,治療組總有效率是95.08%,顯著高于對(duì)照組的77.50%(P<0.05)。治療后,治療組哮鳴音消失、痰鳴音消失、咳嗽消失、喘息消失時(shí)間均顯著短于對(duì)照組(P<0.05)。治療后,兩組患者C-ACT評(píng)分均顯著高于同組治療前(P<0.05);且治療后,治療組C-ACT評(píng)分顯著高于對(duì)照組(P<0.05)。治療后,兩組干擾素-γ(INF-γ)水平較治療前顯著升高,而白細(xì)胞介素-6(IL-6)、細(xì)胞間黏附因子-1(ICAM-1)、白三烯B4(LTB4)水平顯著降低(P<0.05);且治療后,治療組血清學(xué)指標(biāo)改善優(yōu)于對(duì)照組(P<0.05)。結(jié)論 羧甲司坦聯(lián)合丙卡特羅治療小兒支氣管哮喘具有較好的臨床療效,可有效改善患兒臨床癥狀,調(diào)節(jié)患兒機(jī)體血清炎性因子,且安全有效,值得臨床借鑒應(yīng)用

ObjectiveTo explore the clinical effect of carbocisteine combined with procaterol in treatment of bronchial asthma in children. Methods A total of 80 children with bronchial asthma admitted to the Department of Pediatrics of Tianjin Union Medical Center from June 2021 to July 2023 were selected and divided into control group and treatment group according to different treatment methods, with 40 cases in each group. Patients in the control group were po administered with Procaterol Hydrochloride Oral Solution, 3 mL/time, once daily. Patients in the treatment group were po administered with Carbocisteine Tablets on the basis of the control group, 0.5 tablet/time, three times daily. Both groups were treated continuously for 7 d. The clinical efficacy and symptom resolution time of two groups were observed, and the scores of childhood Asthma Control test (C-ACT) and serum inflammatory factors before and after treatment were compared. Results After treatment, the total effective rate of the treatment group was 95.08%, which was significantly higher than that of control group (77.50%, P < 0.05). After treatment, the disappearance time of wheezing, phlegm chirping, cough, and wheezing in treatment group was significantly shorter than that in control group (P < 0.05). After treatment, C-ACT scores in 2 groups were significantly higher than before treatment (P < 0.05). After treatment, the C-ACT score of treatment group was significantly higher than that of control group (P < 0.05). After treatment, the levels of interferon-γ (INF-γ) in two groups were significantly higher than before treatment, but the levels of interleukin-6 (IL-6), intercellular adhesion factor-1 (ICAM-1), and leukotriene B4 (LTB4) were significantly decreased (P < 0.05). After treatment, serological indexes in treatment group were better than those in control group (P < 0.05). Conclusion Carbocisteine combined with procaterol has good clinical efficacy in treatment of bronchial asthma in children, and can effectively improve the clinical symptoms of children, regulate the serum inflammatory factors with good safety and effect, which is worthy of clinical application.

R974

天津市人民醫(yī)院科研項(xiàng)目（2016Y52D004）